PLoS ONE (Jan 2012)

RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.

  • Shiri Weinstein,
  • Rafi Emmanuel,
  • Ashley M Jacobi,
  • Avigdor Abraham,
  • Mark A Behlke,
  • Andrew G Sprague,
  • Tatiana I Novobrantseva,
  • Arnon Nagler,
  • Dan Peer

DOI
https://doi.org/10.1371/journal.pone.0043343
Journal volume & issue
Vol. 7, no. 8
p. e43343

Abstract

Read online

Mantle cell lymphoma is characterized by a genetic translocation results in aberrant overexpression of the CCND1 gene, which encodes cyclin D1. This protein functions as a regulator of the cell cycle progression, hence is considered to play an important role in the pathogenesis of the disease. In this study, we used RNA interference strategies to examine whether cyclin D1 might serve as a therapeutic target for mantle cell lymphoma. Knocking down cyclin D1 resulted in significant growth retardation, cell cycle arrest, and most importantly, induction of apoptosis. These results mark cyclin D1 as a target for mantle cell lymphoma and emphasize the therapeutic potential hidden in its silencing.